Form 4 · Filed Jun 22, 2026, 09:11 PM UTC
ELVN/Enliven Therapeutics, Inc.
Collins Helen Louise — CHIEF MEDICAL OFFICER
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | M | other | 5,000 | $2 | $12,400 | 30,000 |
| Jun 17, 2026 | S | sell | 1,268 | $43 | $54,305 | 28,732 |
| Jun 17, 2026 | S | sell | 2,599 | $44 | $114,018 | 26,133 |
| Jun 17, 2026 | S | sell | 1,133 | $45 | $50,694 | 25,000 |
| Jun 17, 2026 | M | other | 5,000 | — | — | 121,268 |
Source: SEC EDGAR raw filing ↗ · Accession 0001701247-26-000010